Medigen Biotechnology (ROCO:3176) EPS (Basic): NT$-0.78 (TTM As of Dec. 2025)


ROCO:3176 Medigen Biotechnology Corp ROCO:3176
54 GF Score
Price NT$33.40
GF Value NT$49.25
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medigen Biotechnology EPS (Basic)?

Medigen Biotechnology ROCO:3176 +0.75% 54 EPS (Basic) is NT$-0.78 as of Dec. 2025. GuruFocus rates ROCO:3176 with a GF Score™ of 54/100 and a GF Value™ of NT$49.25 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Medigen Biotechnology's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was NT$-0.84. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.78.

Medigen Biotechnology's EPS (Diluted) for the three months ended in Dec. 2025 was NT$-0.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.79.

Medigen Biotechnology's EPS without NRI for the three months ended in Dec. 2025 was NT$-0.83. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.76.

During the past 3 years, the average EPS without NRI Growth Rate was 45.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Medigen Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 45.80% per year. The lowest was -39.50% per year. And the median was 7.70% per year.

Medigen Biotechnology  (ROCO:3176) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Medigen Biotechnology EPS (Basic) Related Terms

Medigen Biotechnology EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology EPS (Basic) Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -4.86 -4.03 -1.47 -0.78

Medigen Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 0.74 -0.27 -0.41 -0.84
ROCO:3176
54GF Score
Medigen Biotechnology Corp ROCO:3176
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Medigen Biotechnology's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-108.803-0)/139.307
=-0.78

Medigen Biotechnology's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-116.808-0)/139.307
=-0.84

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-0.78 mean?
Medigen Biotechnology (ROCO:3176) has a EPS (Basic) of NT$-0.78 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's EPS (Basic) too high?
Medigen Biotechnology's current EPS (Basic) is NT$-0.78. Overall, Medigen Biotechnology has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's EPS (Basic) compare to VRTX and REGN?
Medigen Biotechnology's EPS (Basic) of NT$-0.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current EPS (Basic) is NT$-0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.25, compared to a current price of NT$33.40 — trading 32.2% below its estimated fair value. The current EPS (Basic) is NT$-0.78. Medigen Biotechnology's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current EPS (Basic) is NT$-0.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$33.40 is trading 32.2% below its estimated GF Value™ of NT$49.25. GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.

Key valuation signals for ROCO:3176:

  • EPS (Basic): NT$-0.78
  • GF Value™: NT$49.25 vs. price of NT$33.40 (32.2% below fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
54GF Score

Get the complete analysis for ROCO:3176

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.40
Price
NT$49.25
GF Value